Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tropisetron - An update of its use in the prevention of chemotherapy-induced nausea and vomiting
Autore:
Simpson, K; Spencer, CM; McClellan, KJ;
Indirizzi:
Adis Int Ltd, Auckland 10, New Zealand Adis Int Ltd Auckland New Zealand10 s Int Ltd, Auckland 10, New Zealand
Titolo Testata:
DRUGS
fascicolo: 6, volume: 59, anno: 2000,
pagine: 1297 - 1315
SICI:
0012-6667(200006)59:6<1297:T-AUOI>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
CISPLATIN-INDUCED EMESIS; MODERATELY EMETOGENIC CHEMOTHERAPY; 5-HT3 RECEPTOR ANTAGONISTS; DOUBLE-BLIND; NAVOBAN(R) TROPISETRON; ANTIEMETIC EFFICACY; DELAYED EMESIS; DOLASETRON MESYLATE; PLUS DEXAMETHASONE; DOSE CISPLATIN;
Keywords:
chemotherapy; nausea and vomiting; emesis; tropisetron; pharmacodynamics; pharmacokinetics; therapeutic use;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
71
Recensione:
Indirizzi per estratti:
Indirizzo: Simpson, K Adis Int Ltd, 41 Centorian Dr,Private Bag 65901,Mairangi Bay, Auckland 10,New Zealand Adis Int Ltd 41 Centorian Dr,Private Bag 65901,Mairangi Bay Auckland New Zealand 10
Citazione:
K. Simpson et al., "Tropisetron - An update of its use in the prevention of chemotherapy-induced nausea and vomiting", DRUGS, 59(6), 2000, pp. 1297-1315

Abstract

Tropisetron is a serotonin (5-hydroxytryptamine; 5-HT) antagonist that is primarily used in the prevention of chemotherapy-induced nausea and vomiting. Antagonism of 5-HT3 binding sites in the peripheral and central nervous system is the probable mechanism of prevention of acute nausea and vomiting. Effects on delayed nausea and vomiting are less well understood as these are probably not mediated solely by 5-HT3 receptors. Tropisetron monotherapy is effective for the control of acute, and to a lesser extent delayed, nausea and vomiting in patients receiving moderately to severely emetogenic chemotherapy. The combination of dexamethasone and tropisetron is more effective than monotherapy. Complete control of cisplatin-induced nausea and vomiting was obtained in 69 to 97% of patients receiving the combination compared with 46 to 80% receiving tropisetron monotherapyin randomised trials. There were generally no significant differences between the control of acute or delayed nausea and vomiting provided by tropisetron, ondansetron or granisetron in randomised, comparative trials. The antiemetic efficacy of tropisetron was maintained over multiple cycles of chemotherapy. Most comparative studies showed tropisetron monotherapy to be more effective than metoclopramide in controlling acute nausea and vomiting, with the exception of 1 study which showed similar efficacy. However, high dose metoclopramide plus dexamethasone provided similar control of delayed emesis to tropisetron plus dexamethasone. Tropisetron is also effective in children, including those who responded poorly to previous antiemetic treatment. Tropisetron and ondansetron generally have similar efficacies in this population. The drug enhanced patients' quality of life and was well tolerated by adults and children alike. The recommended oral and IV dosage of tropisetron is 5mg once daily; thereis no increase in efficacy with doses >5mg. Conclusions: Tropisetron is similar to other 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting in both adultsand children. It is suitable as first-line therapy (combined with a corticosteroid) for the prevention of acute nausea and vomiting in patients treated with moderately to severely emetogenic chemotherapeutic agents. This combination is also moderately effective in the prevention of delayed nausea and vomiting.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 07:02:07